When we restricted our analyses to breast cancer tumors that were either estrogen-receptor or progesterone-receptor positive (ER+/PR+), the overall pattern of estimated risks was generally similar to those observed for all tumor types considered in our original analysis (data not shown). This evidence concerns the gene PGR and breast cancer.